SA writer David Zanoni recommends having a look at Celgene (CELG -1.5%), citing its 5...

|About: Celgene Corporation (CELG)|By:, SA News Editor

SA writer David Zanoni recommends having a look at Celgene (CELG -1.5%), citing its 5 FDA-approved cancer drugs and its extensive pipeline. What Zanoni really likes, though, is Celgene's earnings growth, which is forecast at an average of 25% over the next five years. If that is achieved, "Celgene's stock price of (about) $65 should grow to around $200."